Skip Navigation
  Search Menu
Find an Expert


Leonido Luznik, M.D.

Photo of Dr. Leonido Luznik, M.D.

Professor of Oncology


Expertise: Bone Marrow Transplant, Graft-versus-Host Disease, Hematologic Malignancies, Medical Oncology

Research Interests: Graft vs. Host Diseases; Leukemia; Non-Hodgkin's Lymphoma

Request an Appointment

I live in Maryland

Request an appointment through MyChart!

I live outside of Maryland

Request Appointment

I live outside of the United States

Request Appointment


Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-955-8964

401 N. Broadway
Harry and Jeanette Weinberg Building
Baltimore, MD 21231 map
Phone: 410-502-7732
Fax: 410-614-1005


1990-1991 House Officer, University of Zagreb School of Medicine, Zagreb, Croatia more


  • Professor of Oncology

Departments / Divisions

Centers & Institutes



  • MD, University Hospital Centre of Zagreb (1990)


  • Univ Of Arizona College Of Medicine / Internal Medicine (1997)


  • University of California / Molecular Biology (1994)
  • Johns Hopkins University School of Medicine / Medical Oncology (2001)

Research & Publications

Research Summary

Dr. Luznik's primary research interest is in the area of allogeneic blood and marrow stem cell transplantation (alloBMT). In the laboratory, there are two main areas of ongoing research. The first area focuses on understanding the mechanisms of antitumor immunity after alloBMT. The strategy is to induce immune response against antigens expressed on the tumor (tumor-specific antigens) but not on the normal host hematopoietic and epithelial tissue.

A second area of interest focuses on understanding the critical cellular and molecular mechanisms of acute and chronic GVHD. The long-term goal of these studies is to translate them into the clinic to achieve better antitumor efficacy of alloBMT and to extend the application of this procedure to patients with non-hematopoietic disorders by early induction of tolerance and better prevention of acute and chronic GVHD.

Dr. Luznik's clinical interests are focused on the translation of the concepts developed in the laboratory to early phase clinical trials. He currently leads the multi-institutional clinical trial using high-dose cyclophosphamide as single-agent short course GVHD prophylaxis. (Principal Investigator: L. Luznik; Identifier: NCT 00809276). As a part of this clinical trial, his laboratoty is also conducting a systematic study of the correlates of T-cell immune recovery with the goal of identifying critical mechanisms behind the unique ability of high-dose cyclophosphamide to prevent acute and chronic GVHD.

Clinical Trial Keywords

single-agent, short course GVHD prophylaxis, high-dose cyclophosphamide, Lymphoma, Leukemia

Selected Publications

Luznik, L., O’Donnell, P.V., Symons, H.J., Chen, A.R., Leffell, M.S., Zahurak, M., Piantadosi, S., Gooley, T.A., Kaup, M., Ambinder, R.F., Huff, C.A., Matsui, W.H., Bolaños-Meade, J., Borrello, I., Powell, J.D., Flowers, M.,Brodsky, R.A., Sandmaier, B.M., Storb, R.F., Jones, R.J. and E. J. Fuchs: HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-650

Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith, BD, Brodsky R, Huff C, Borrello I, Matsui W, Powell JD, Kasamon Y, Goodman SN, Hess A, Levitsky HI, Ambinder RF, Jones RJ, Fuchs EJ. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus host disease. Blood. 2010;115(16):3224-3230

Kanakry, CG., O’Donnell, PV., Furlong, T., de Lima, MJ., Wei, W., Medeot, M., Mielcarek, M., Champlin, RE., Jones, RJ., Thall, PF., Andersson, BS., and L. Luznik: Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. JCO. 2014; 32(31):3497-505

Kanakry CG., Ganguly S., Zahurak M., Bolaños-Meade J., Thoburn C., Perkins B., Fuchs EJ, Jones RJ, Hess AD, L. Luznik: Aldehyde dehydrogenase upregulation drives human regulatory T cell resistance to post-transplantation cyclophosphamide. Sci. Transl. Med. 2013; 5(211)ra157

Kanakry, CG, Fuchs, EJ and L. Luznik: Modern approaches to HLA-haploidenticalblood or marrow transplantation. Nature Rev. Clin. Oncol. 13. 1-14. 2016

Activities & Honors


  • American Society of Bone Marrow Transplantation, 1998
  • American Society of Hematology, 1998

Professional Activities

  • Diplomate, Internal Medicine, 1997
  • Diplomate, Hematology, 2001
  • Diplomate, Medical Oncology, 2002

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 


Is this you? Edit Profile